Compare Amylx Pharmaceuticals Inc (AMLX) vs Hilton Hotels Corporation Common Stock (HLT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Hilton Hotels Corporation Common Stock — how do they compare? Amylx Pharmaceuticals Inc trades at $17.18 (market cap $1.98B), while Hilton Hotels Corporation Common Stock trades at $334.9 (market cap $76.37B). The key difference: Hilton Hotels Corporation Common Stock is far larger — about 38.6× Amylx Pharmaceuticals Inc's market cap, and Hilton Hotels Corporation Common Stock pays a 0.18% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | HLT | |
|---|---|---|
Market Cap | $1.98B | $76.37B |
Sector | Health | Consumer Cyclical |
52-Week High | $18.70 | $350.22 |
52-Week Low | $7.64 | $256.75 |
Enterprise Value | $1.70B | $88.87B |
Dividend Yield | — | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
Hilton Worldwide (HLT) trades at $335.48, down 0.64% on the day, with a bullish technical signal and strong earnings beat history. Revenue grew to $12.04B in 2025 with a net income margin of 12.56%, though valuation multiples appear elevated with a P/E of 51.22. Recent news highlights brand campaigns and property renovations, supporting positive sentiment.
Outlook remains favorable with analyst consensus price target of $342.11 implying modest upside. Risks include high debt levels and sensitivity to travel demand fluctuations. The stock offers growth exposure to hospitality recovery but requires monitoring of leverage and macroeconomic trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Hilton Hotels Corporation Common Stock
Hilton Worldwide Holdings operates 1,074,791 rooms across its 18 brands addressing the midscale through luxury segments as of Dec. 31, 2021. Hampton and Hilton are the two largest brands by total room count at 28% and 21%, respectively, as of Dec. 31, 2021. Recent brands launched over the last few years include Home2, Curio, Canopy, Tru, and Tempo. Managed and franchised represent the vast majority of adjusted EBITDA, predominantly from the Americas regions.
Read more on HLT →
